AI gen brain scan concept
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Telix Pharmaceuticals (ASX:TLX) has announced its receipt of fast track status from the US FDA within the approvals chain for the assessment of Telix’s PET-scan brain cancer imaging agent Pixclara.

The company is focusing particularly on gliomas in the brain – a tumour that forms from glial cells acting abnormally. Glial cells help connect neurons in the brain, making ‘glioma’ and ‘brain cancer’ effectively interchangeable.

Fast track status does not guarantee eventual commercialisation approval from the United States’ food and drug regulator but does ensure a relatively faster progression through the bureaucratic ecosystem.

Pixclara – F-floretyrosine (or, F-FET) – is designed for injection into the human body before a PET scan. Imaging agents are, in pub language, lightly radioactive materials that ‘show up’ on scanners, allowing a high-definition scan of the internal anatomy of a patient.

Telix noted on Wednesday its fast track status win is due to a relative lack of treatment viability in glioma patients.

“With low survival rates and the need to make rapid decisions, precision imaging is paramount,” Telix wrote on Wednesday.

“Pixclara is also being developed as the “companion” theranostic imaging agent for TLX101, Telix’s investigational neuro-oncology drug candidate,” the company added.

Management further outlined the dire situation most patients face at present.

“Gliomas are the most common primary brain tumours of the central nervous system. Conventional imaging with MRI6 often yields inconclusive results in characterising recurrent disease and therefore delays time-sensitive decision making,” Telix CEO Kevin Richardson said.

“Limitations of conventional imaging techniques include the lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumour progression or treatment-related causes.”

TLX last traded at $19.97.

TLX by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…